Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

doi:10.1016/S1474-4422(19)30319-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

The Lancet. Neurology - 1 Jan 2020

Simuni Tanya, Uribe Liz, Cho Hyunkeun Ryan, Caspell-Garcia Chelsea, Coffey Christopher S, Siderowf Andrew, Trojanowski John Q, Shaw Leslie M, Seibyl John, Singleton Andrew, Toga Arthur W, Galasko Doug, Foroud Tatiana, Tosun Duygu, Poston Kathleen, Weintraub Daniel, Mollenhauer Brit, Tanner Caroline M, Kieburtz Karl, Chahine Lana M, Reimer Alyssa, Hutten Samantha J, Bressman Susan, Marek Kenneth

Abstract excerpt

BACKGROUND: The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational, longitudinal cohort study of participants with Parkinson's disease, healthy controls, and carriers of the most common Parkinson's disease-related genetic mutations, which aims to define biomarkers of Parkinson's disease diagnosis and progression. All participants are assessed annually with a battery of motor and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain

Share to Cross-Sectional Studies

Share to Dopamine Plasma Membrane Transport Proteins

Share to Glucosylceramidase

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinson Disease

Share to Prodromal Symptoms

Source

Open in PubMed Open full text

Identifiers

PMID: 31678032
DOI: 10.1016/S1474-4422(19)30319-9
PMCID: PMC6956652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.PMID 31678032Read ↗

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.Semantic proximity Read ↗

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.Semantic proximity Read ↗

Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.Semantic proximity Read ↗

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.Semantic proximity Read ↗

Apathy: an underestimated feature in GBA and LRRK2 non-manifesting mutation carriersSemantic proximity Read ↗

Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.Semantic proximity Read ↗

Quantitative dopamine transporter imaging assessment in Parkinson's disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study.Semantic proximity Read ↗

Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohortsSemantic proximity Read ↗

The challenges with the identification of Parkinson's disease subtypes.Semantic proximity Read ↗

Genome-wide association study of Parkinson’s disease progression biomarkers in 12 longitudinal patients’ cohortsSemantic proximity Read ↗

Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.Semantic proximity Read ↗

SAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.